Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/v13061141 http://scihub22266oqcxt.onion/10.3390/v13061141 34198530!8231802!34198530     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Viruses 2021 ; 13 (6): ä Nephropedia Template TP {{tp|p=34198530|t=2021. Modeling within-Host SARS-CoV-2 Infection Dynamics and Potential Treatments |pdf=|usr=}}{{34198530}} gab.com Text Modeling within-Host SARS-CoV-2 Infection Dynamics and Potential Treatments JO: Viruses http://www.kidney.de/pget.php?&tw=1&pmid=34198530 #FOAvip The goal of this study was to develop a mathematical model to simulate the actions of drugs that target SARS-CoV-2 virus infection. To accomplish that goal, we have developed a mathematical model that describes the control of a SARS-CoV-2 infection by the innate and adaptive immune components. Invasion of the virus triggers the innate immunity, whereby interferon renders some of the target cells resistant to infection, and infected cells are removed by effector cells. The adaptive immune response is represented by plasma cells and virus-specific antibodies. The model is parameterized and then validated against viral load measurements collected in COVID-19 patients. We apply the model to simulate three potential anti-SARS-CoV-2 therapies: (1) Remdesivir, a repurposed drug that has been shown to inhibit the transcription of SARS-CoV-2, (2) an alternative (hypothetical) therapy that inhibits the virus' entry into host cells, and (3) convalescent plasma transfusion therapy. Simulation results point to the importance of early intervention, i.e., for any of the three therapies to be effective, it must be administered sufficiently early, not more than a day or two after the onset of symptoms. The model can serve as a key component in integrative platforms for rapid in silico testing of potential COVID-19 therapies and vaccines. Twit Text FOAVip Modeling within-Host SARS-CoV-2 Infection Dynamics and Potential Treatments ????Viruses http://www.kidney.de/pget.php?&tw=1&pmid=34198530 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34198530 #FOAvip English Wikipedia <ref>{{Cite pmid|34198530}}</ref> Modeling within-Host SARS-CoV-2 Infection Dynamics and Potential Treatments #MMPMID34198530 Sadria M; Layton AT Viruses 2021[Jun]; 13 (6): ä PMID34198530show ga The goal of this study was to develop a mathematical model to simulate the actions of drugs that target SARS-CoV-2 virus infection. To accomplish that goal, we have developed a mathematical model that describes the control of a SARS-CoV-2 infection by the innate and adaptive immune components. Invasion of the virus triggers the innate immunity, whereby interferon renders some of the target cells resistant to infection, and infected cells are removed by effector cells. The adaptive immune response is represented by plasma cells and virus-specific antibodies. The model is parameterized and then validated against viral load measurements collected in COVID-19 patients. We apply the model to simulate three potential anti-SARS-CoV-2 therapies: (1) Remdesivir, a repurposed drug that has been shown to inhibit the transcription of SARS-CoV-2, (2) an alternative (hypothetical) therapy that inhibits the virus' entry into host cells, and (3) convalescent plasma transfusion therapy. Simulation results point to the importance of early intervention, i.e., for any of the three therapies to be effective, it must be administered sufficiently early, not more than a day or two after the onset of symptoms. The model can serve as a key component in integrative platforms for rapid in silico testing of potential COVID-19 therapies and vaccines. |*Adaptive Immunity[MESH] |*COVID-19 Drug Treatment[MESH] |*Immunity, Innate[MESH] |*Models, Theoretical[MESH] |Adenosine Monophosphate/analogs & derivatives/therapeutic use[MESH] |Alanine/analogs & derivatives/therapeutic use[MESH] |Antibodies, Viral/blood[MESH] |Antiviral Agents/therapeutic use[MESH] |COVID-19 Serotherapy[MESH] |COVID-19/immunology/therapy[MESH] |Host-Pathogen Interactions/*drug effects/immunology[MESH] |Humans[MESH] |Immunization, Passive/methods[MESH]Modeling within-Host SARS-CoV-2 Infection Dynamics and Potential Treat(epmc).pdf DeepDyve Pubget Overpricing